Breast cancer treatment pipeline has over 1,000 drugs in development
The breast cancer treatment pipeline’s exceptional levels of activity and innovation may significantly alter the clinical and commercial landscape of the disease market over the next decade, according to business intelligence provider GBI Research.
The breast cancer treatment pipeline comprises a staggering 1,050 drugs in active development across all stages and 347 first-in-class programmes.
The company’s latest report states that factors driving such innovation and potential for breakthrough drugs include a very large and growing patient pool, a well-established market with multiple unmet needs, and a robust understanding of the disease pathophysiology, facilitating the development of novel compounds that may fill such needs.
Click on this link for more information.
